Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
Not yet recruiting · NCT06869174 · Registry updated 2025-03-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary | Cancer of Unknown Primary | Not yet recruiting | Phase 2 | 2025-03-12 | NCT06869174 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhiguo Luo, MD, PhD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 257 |